

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

July 2026

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white wavy lines on a grey background.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 July 2026	3
Section H changes to Part II	7
Index	16

Summary of decisions

EFFECTIVE 1 JULY 2026

- Alfentanil (Medsurge) inj 0.5 mg per ml, 2 ml ampoule – price decrease and addition of PSS
- Bacillus Calmette-Guerin (BCG) (OncoTICE) inj 2-8 × 10⁸ CFU vial – price increase
- Benralizumab (Fasenra) inj 30 mg per ml, 1 ml prefilled pen – new Pharmacode listing
- Budesonide with glycopyrronium and eformoterol (Breztri Aerosphere) aerosol inhaler budesonide 160 mcg with glycopyrronium 7.2 mcg and formoterol 5 mcg per dose – new Pharmacode listing
- Calcitonin (Miacalcic) inj 100 iu per ml, 1 ml ampoule – Pharmacode 2709317 to be delisted 1 October 2026
- Carmustine (BiCNU) inj 100 mg vial – addition of PSS
- Carmustine (BiCNU S29 and Novadoz) inj 100 mg vial – to be delisted 1 December 2026
- Cefalexin (Cefalexin Sandoz) grans for oral liq 50 mg per ml, 100 ml – new listing
- Chloramphenicol cap 250 mg and 500 mg – new listing
- Cinchocaine hydrochloride with hydrocortisone (Proctosedyl) oint 5 mg with hydrocortisone 5 mg per g, 30 g and suppos 5 mg with hydrocortisone 5 mg per g – price increase
- Ciprofloxacin (Ipca-Ciprofloxacin) tab 250 mg and 750 mg – addition of PSS
- Ciprofloxacin (Ipca-Ciprofloxacin) tab 500 mg – price decrease and addition of PSS
- Colchicine (Colchicine Indoco) tab 500 mcg – new listing and addition of PSS
- Colchicine (Colgout) tab 500 mcg – to be delisted from 1 December 2026
- Cyclopentolate hydrochloride (Cyclogyl) eye drops 1%, 15 ml – price increase
- Darunavir (Darunavir Viatris) tab 400 mg and tab 600 mg – price decrease and addition of PSS
- Efavirenz with emtricitabine and tenofovir disoproxil (Tenofovir Efavirenz Emtricitabine(Mylan)) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) – new listing
- Emulsifying ointment (Evara Emulsifying Ointment) oint BP, 500 g – price decrease and addition of PSS
- Ephedrine (Ephedrine Juno) inj 3 mg per ml, 10 ml syringe – addition of PSS
- Ephedrine (Ephedrine Aguettant) inj 3 mg per ml, 10 ml syringe – delisted 1 July 2026
- Ephedrine (Max Health) inj 30 mg per ml, 1 ml ampoule – price increase and addition of PSS
- Etanercept (Enbrel) inj 25 mg autoinjector, inj 25 mg vial, inj 50 mg autoinjector and inj 50 mg syringe – amended restriction criteria

Summary of decisions – effective 1 July 2026 (continued)

- Ezetimibe (Ezetimibe Sandoz) tab 10 mg – price decrease and addition of PSS
 - Febuxostat (Febuxostat (Teva)) tab 80 mg and 120 mg – price decrease and addition of PSS
 - Fluconazole (Diflucan) inj 2 mg per ml, 50 ml vial and inj 2 mg per ml, 100 ml vial – new listing
 - Iodixanol (Visipaque) – price increase
 - Inj 270 mg per ml (iodine equivalent), 50 ml bottle
 - Inj 270 mg per ml (iodine equivalent), 100 ml bottle
 - Inj 320 mg per ml (iodine equivalent), 50 ml bottle
 - Inj 320 mg per ml (iodine equivalent), 100 ml bottle
 - Inj 320 mg per ml (iodine equivalent), 200 ml bottle
 - Iohexol (Omnipaque) – price increase
 - Inj 240 mg per ml (iodine equivalent), 50 ml bottle
 - Inj 300 mg per ml (iodine equivalent), 10 ml bottle
 - Inj 300 mg per ml (iodine equivalent), 50 ml bottle
 - Inj 300 mg per ml (iodine equivalent), 100 ml bottle
 - Inj 350 mg per ml (iodine equivalent), 50 ml bottle
 - Inj 350 mg per ml (iodine equivalent), 100 ml bottle
 - Inj 350 mg per ml (iodine equivalent), 200 ml bottle
 - Inj 350 mg per ml, 500 ml bottle
 - Lansoprazole (Lansoprazole (Viatris)) tab orodispersible 30 mg – new listing
 - Macrogol 3350 with potassium chloride and sodium chloride with/without sodium sulfate, sodium ascorbate, ascorbic acid (Plenvu) powd for oral soln 100g with potassium chloride 1g, sodium chloride 2g and sodium sulfate 9g per sach(1), powd for oral soln 40g with potassium chloride 1.2g and sodium chloride 3.2g per sach(1) and powd for oral soln ascorbic acid 7.54g and sodium ascorbate 48.11g per sach(1) – addition of PSS
 - Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (Movicol) powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – price decrease
 - Magnesium sulphate (Martindale) inj 2 mmol per ml, 5 ml ampoule – price decrease and addition of PSS
 - Mebeverine hydrochloride (Colofac) tab 135 mg – price decrease and addition of PSS
 - Melphalan (Melpha) inj 50 mg vial – price decrease and addition of PSS
 - Meropenem (Meropenem-AFT) inj 500 mg vial and inj 1 g vial – price decrease and addition of PSS
 - Metaraminol (Torbay) inj 10 mg per ml, 1 ml ampoule – price decrease and addition of PSS
-

Summary of decisions – effective 1 July 2026 (continued)

- Methotrexate (Methotrexate Pharmascience) inj 7.5 mg prefilled syringe – new listing
- Methylprednisolone aceponate (Advantan) crm 0.1% and oint 0.1%, 15 g – addition of PSS
- Moxifloxacin (Moxifloxacin Kabi) inj 1.6 mg per ml, 250 ml bottle – price decrease and addition of PSS
- Moxifloxacin (Moximed) tab 400 mg – new listing and addition of PSS
- Moxifloxacin (Avelox) tab 400 mg – to be delisted 1 December 2026
- Multivitamins (Mvite) tab (BPC cap strength) – price decrease and addition of PSS
- Nimodipine (Nimotop) tab 30 mg – new Pharmacode listing
- Niraparib (Zejula) cap 100 mg – to be delisted 1 October 2026
- Oxybutynin (Alchemy Oxybutynin) tab 5 mg – addition of PSS
- Paediatric oral feed 1 kcal/ml (Pediasure (chocolate)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 200 ml bottle – Pharmacode 2702754 to be delisted 1 August 2026
- Paediatric oral feed 1 kcal/ml (Pediasure (chocolate)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 200 ml bottle – new listing
- Paracetamol (Pacimol) tab 500 mg - blister pack - 1,000 tablet pack – price decrease and addition of PSS
- Paraffin liquid with wool fat (Poly-Visc) eye oint 3% with wool fat 3%, 3.5 g – new Pharmacode listing
- Promethazine hydrochloride (XGen) inj 25 mg per ml, 1 ml ampoule – new listing
- Quetiapine (Quetapel) tab 25 mg, 100 mg, 200 mg and 300 mg – price decrease and addition of PSS
- Rifampicin (Rifadin) inj 600 mg vial – addition of PSS
- Rizatriptan (Rizatriptan Rising) tab orodispersible 10 mg – new listing
- Rizatriptan (Rizamelt) tab orodispersible 10 mg – price decrease and addition of PSS
- Rizatriptan (Rizatriptan Viatrix) tab orodispersible 10 mg – price decrease
- Rosuvastatin (Rosuvastatin Mylan) tab 5 mg, 10 mg, 20 mg and 40 mg – new listing
- Simvastatin (Simvastatin Viatrix) tab 10 mg, 20 mg, 40 mg and 80 mg – price decrease and addition of PSS
- Sodium citro-tartrate (Ural) grans eff 4 g sachets – price decrease and addition of PSS
- Sunitinib (Sunitinib Rex) cap 12.5 mg, 25 mg and 50 mg – amended restriction criteria
- Suxamethonium chloride (Martindale) inj 50 mg per ml, 2 ml ampoule – price decrease and addition of PSS
- Tamoxifen citrate (Tamoxifen Sandoz) tab 10 mg and 20 mg – addition of PSS
- Temozolomide (Temozolomide (Devatis)) cap 5 mg – new listing

Summary of decisions – effective 1 July 2026 (continued)

- Temozolomide cap 5 mg (Temaccord, Temozolomide Taro and Temozolomide (Devatis)), cap 20 mg (Temaccord), cap 100 mg (Temaccord), cap 140 mg (Temaccord) and cap 250 mg (Temaccord) – amended restriction criteria
- Tenecteplase inj 50 mg vial – delisted 1 July 2026
- Tenecteplase (Metalyse) inj 50 mg vial with diluent – new listing
- Teriflunomide (Teriflunomide Aurobindo) tab 14 mg – new listing
- Testosterone undecanoate (Gonadron) inj 250 mg per ml, 4 ml vial – new listing and addition of PSS
- Testosterone undecanoate (Reandron 1000) inj 250 mg per ml, 4 ml vial – to be delisted 1 December 2026
- Thiamine hydrochloride (Thiamine-REX) tab 50 mg – new listing and addition of PSS
- Thiamine hydrochloride (Thiamine Multichem) tab 50 mg – to be delisted 1 December 2026
- Triamcinolone acetonide inj 10 mg per ml, 1 ml ampoule (Kenacort-A 10) and inj 40 mg per ml, 1 ml ampoule (Kenacort-A 40) – addition of PSS
- Triamcinolone acetonide (Kenalog in Orabase) paste 0.1%, 5 g – price decrease and addition of PSS
- Tropicamide (Mydriacyl) eye drops 0.5% and 1%, 15 ml – price increase
- Ursodeoxycholic acid (APO-Ursodeoxycholic Acid) cap 250 mg – new listing
- Valaciclovir (Valaciclovir Viatris) tab 500 mg – new listing
- Vancomycin (Vancomycin Viatris) inj 500 mg vial, 10 inj – new pack size listing and addition of PSS
- Vancomycin (Vancomycin Viatris) inj 500 mg vial, 1 inj – to be delisted 1 February 2027

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 July 2026

ALIMENTARY TRACT AND METABOLISM

7	CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE (↑ price) Oint 5 mg with hydrocortisone 5 mg per g..... 17.03 Suppos 5 mg with hydrocortisone 5 mg per g 11.24	30 g 12	Proctosedyl Proctosedyl
7	MEBEVERINE HYDROCHLORIDE (↓ price and addition of PSS) Tab 135 mg – 5% DV Dec-26 to 2029 8.00	90	Colofac
8	LANSOPRAZOLE (new listing) Tab orodispersible 30 mg 5.43	100	Lansoprazole (Viatris)
14	URSODEOXYCHOLIC ACID (new listing) → Cap 250 mg 62.00	100	APO-Ursodeoxycholic Acid
15	MACROGOL 3350 WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE WITH/WITHOUT SODIUM SULFATE, SODIUM ASCORBATE, ASCORBIC ACID (addition of PSS) Powd for oral soln 100g with potassium chloride 1g, sodium chloride 2g and sodium sulfate 9g per sach(1), powd for oral soln 40g with potassium chloride 1.2g and sodium chloride 3.2g per sach(1) and powd for oral soln ascorbic acid 7.54g and sodium ascorbate 48.11g per sach(1) – 5% DV Dec-26 to 2029 18.52	3	Plenvu
16	MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE (↓ price) Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg..... 10.15	30	Movicol
25	MAGNESIUM SULPHATE (↓ price and addition of PSS) Inj 2 mmol per ml, 5 ml ampoule – 5% DV Feb-27 to 2029 26.27	10	Martindale
26	TRIAMCINOLONE ACETONIDE (↓ price and addition of PSS) Paste 0.1% – 5% DV Dec-26 to 2029 3.57	5 g	Kenalog in Orabase
27	MULTIVITAMINS (↓ price and addition of PSS) Tab (BPC cap strength) – 5% DV Dec-26 to 2029 21.65	1,000	Mvite
28	THIAMINE HYDROCHLORIDE (brand change and addition of PSS) Tab 50 mg – 5% DV Dec-26 to 2028 3.89 Note – Thiamine Multichem tab 50 mg to be delisted from 1 December 2026.	100	Thiamine-REX

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2026 (continued)

BLOOD AND BLOOD FORMING ORGANS

39	TENECTEPLASE (delisted) Inj 50 mg vial Note – Tenecteplase inj 50 mg vial delisted 1 July 2026.			
39	TENECTEPLASE (new listing) Inj 50 mg vial with diluent	2,390.00	1	Metalyse

CARDIOVASCULAR SYSTEM

50	NIMODIPINE (new Pharmacode listing) Tab 30 mg – 5% DV Feb-26 to 2028	350.00	100	Nimotop
	Note – This is a new Pharmacode listing, 2731568.			
53	ROSUVASTATIN (new listing) → Tab 5 mg..... → Tab 10 mg..... → Tab 20 mg..... → Tab 40 mg.....	1.29 1.69 2.71 4.55	30 30 30 30	Rosuvastatin Mylan Rosuvastatin Mylan Rosuvastatin Mylan Rosuvastatin Mylan
54	SIMVASTATIN (↓ price and addition of PSS) Tab 10 mg – 5% DV Dec-26 to 2029 Tab 20 mg – 5% DV Dec-26 to 2029 Tab 40 mg – 5% DV Dec-26 to 2029 Tab 80 mg – 5% DV Dec-26 to 2029	1.67 2.35 3.85 8.75	90 90 90 90	Simvastatin Viatris Simvastatin Viatris Simvastatin Viatris Simvastatin Viatris
54	EZETIMIBE (↓ price and addition of PSS) Tab 10 mg – 5% DV Dec-26 to 2029	1.44	30	Ezetimibe Sandoz
55	EPHEDRINE (addition of PSS) Inj 3 mg per ml, 10 ml syringe – 5% DV Dec-26 to 2029	142.00	10	Ephedrine Juno
55	EPHEDRINE (delisted) Inj 3 mg per ml, 10 ml syringe	142.00	10	Ephedrine Aguettant
	Note – Ephedrine Aguettant inj 3 mg per ml, 10 ml syringe delisted 1 July 2026.			
55	EPHEDRINE (↑ price and addition of PSS) Inj 30 mg per ml, 1 ml ampoule – 5% DV Dec-26 to 2029	42.89	10	Max Health
56	METARAMINOL (↓ price and addition of PSS) Inj 10 mg per ml, 1 ml ampoule – 5% DV Dec-26 to 2029	50.35	10	Torbay

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2026 (continued)

DERMATOLOGICALS

70	EMULSIFYING OINTMENT (↓ price and addition of PSS) Oint BP, 500 g – 5% DV Dec-26 to 2029	2.95	500 g	Evara Emulsifying Ointment
	Note: DV limit applies to pack sizes of greater than 200 g			
71	METHYLPREDNISOLONE ACEPONATE (addition of PSS) Crm 0.1% – 5% DV Dec-26 to 2029	4.95	15 g	Advantan
	Oint 0.1% – 5% DV Dec-26 to 2029	4.95	15 g	Advantan

GENITO-URINARY SYSTEM

77	SODIUM CITRO-TARTRATE (↓ price and addition of PSS) Grans eff 4 g sachets – 5% DV Dec-26 to 2029	3.33	28	Ural
78	OXYBUTYNIN (addition of PSS) Tab 5 mg – 5% DV Dec-26 to 2029	5.42	100	Alchemy Oxybutynin

HORMONE PREPARATIONS

79	TESTOSTERONE UNDECANOATE (brand change and addition of PSS) Inj 250 mg per ml, 4 ml vial – 5% DV Dec-26 to 2028	27.50	1	Gonadron
	Note – Reandron 1000 inj 250 mg per ml, 4 ml vial to be delisted from 1 December 2026.			
79	CALCITONIN (delisting) Inj 100 iu per ml, 1 ml ampoule.....	121.00	5	Miacalcic
	Note – Miacalcic inj 100 iu per ml to be delisted from 1 October 2026. This delist applies to Pharmacode 2709317.			
81	TRIAMCINOLONE ACETONIDE (addition of PSS) Inj 10 mg per ml, 1 ml ampoule – 5% DV Dec-26 to 2028	21.42	5	Kenacort-A 10
	Inj 40 mg per ml, 1 ml ampoule – 5% DV Dec-26 to 2028	52.63	5	Kenacort-A 40

INFECTIONS

91	MEROPENEM (↓ price and addition of PSS) → Inj 500 mg vial – 5% DV Dec-26 to 2029	28.87	10	Meropenem-AFT
	→ Inj 1 g vial – 5% DV Dec-26 to 2029	38.70	10	Meropenem-AFT
91	CEFALEXIN (new listing) Grans for oral liq 50 mg per ml – 5% DV Dec-26 to 2028	7.54	100 ml	Cefalexin Sandoz
	Note – this is a new Pharmacode listing, 2714086.			
95	CIPROFLOXACIN (addition of PSS) → Tab 250 mg – 5% DV Dec-26 to 2029	1.95	28	Ipca-Ciprofloxacin
	→ Tab 750 mg – 5% DV Dec-26 to 2029	4.80	28	Ipca-Ciprofloxacin
95	CIPROFLOXACIN (↓ price and addition of PSS) → Tab 500 mg – 5% DV Dec-26 to 2029	2.70	28	Ipca-Ciprofloxacin

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2026 (continued)

95	MOXIFLOXACIN (brand change and addition of PSS) → Tab 400 mg – 5% DV Dec-26 to 2029	25.98	5	Moximed
	Note – Avelox tab 400 mg to be delisted from 1 December 2026.			
95	MOXIFLOXACIN (↓ price and addition of PSS) → Inj 1.6 mg per ml, 250 ml bottle – 5% DV Dec-26 to 2029	372.10	10	Moxifloxacin Kabi
97	CHLORAMPHENICOL (new listing) → Cap 250 mg → Cap 500 mg			
98	VANCOMYCIN (new pack size listing and addition of PSS) → Inj 500 mg vial – 5% DV Feb-27 to 2029	28.50	10	Vancomycin Viatriis
	Note – Vancomycin Viatriis inj 500 mg vial, 1 inj pack to be to be delisted 1 February 2027.			
99	FLUCONAZOLE (new listing) → Inj 2 mg per ml, 50 ml vial	17.66	1	Diflucan
	→ Inj 2 mg per ml, 100 ml vial	33.84	1	Diflucan
103	RIFAMPICIN (addition of PSS) → Inj 600 mg vial – 5% DV Dec-26 to 2029	134.98	1	Rifadin
106	EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL (new listing) → Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate).....	106.88	30	Tenofovir Efavirenz Emtricitabine (Mylan)
107	DARUNAVIR (↓ price and addition of PSS) → Tab 400 mg – 5% DV Dec-26 to 2029	115.00	60	Darunavir Viatriis
	→ Tab 600 mg – 5% DV Dec-26 to 2029	130.00	60	Darunavir Viatriis
108	VALACICLOVIR (new listing) Tab 500 mg.....	13.50	42	Valaciclovir Viatriis

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2026 (continued)

MUSCULOSKELETAL SYSTEM

118	COLCHICINE (brand change and addition of PSS) Tab 500 mcg – 5% DV Dec-26 to 2028	3.15	100	Colchicine Indoco
	Note – Colgout tab 500 mcg to be delisted from 1 December 2026.			
118	FEBUXOSTAT (↓ price and addition of PSS) → Tab 80 mg – 5% DV Dec-26 to 2029	4.66	28	Febuxostat (Teva)
	→ Tab 120 mg – 5% DV Dec-26 to 2029	11.67	28	Febuxostat (Teva)
119	SUXAMETHONIUM CHLORIDE (↓ price and addition of PSS) Inj 50 mg per ml, 2 ml ampoule – 5% DV Dec-26 to 2029	27.61	10	Martindale

NERVOUS SYSTEM

127	PARACETAMOL (↓ price and addition of PSS) Tab 500 mg - blister pack - 1,000 tablet pack – 5% DV Dec-26 to 2029	12.06	1,000	Pacimol
127	ALFENTANIL (↓ price and addition of PSS) Inj 0.5 mg per ml, 2 ml ampoule – 5% DV Dec-26 to 2029	6.99	5	Medsurge
134	RIZATRIPTAN (new listing) Tab orodispersible 10 mg	2.46	18	Rizatriptan Rising
134	RIZATRIPTAN (↓ price and addition of PSS) Tab orodispersible 10 mg – 5% DV Dec-26 to 2029	4.10	30	Rizamelt
134	RIZATRIPTAN (↓ price) Tab orodispersible 10 mg	4.10	30	Rizatriptan Viatrix
137	QUETIAPINE (↓ price and addition of PSS) Tab 25 mg – 5% DV Dec-26 to 2029	2.14	90	Quetapel
	Tab 100 mg – 5% DV Dec-26 to 2029	5.91	90	Quetapel
	Tab 200 mg – 5% DV Dec-26 to 2029	9.93	90	Quetapel
	Tab 300 mg – 5% DV Dec-26 to 2029	14.48	90	Quetapel
142	TERIFLUNOMIDE (new listing) Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted. → Tab 14 mg.....	282.81	30	Teriflunomide Aurobindo

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2026 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

152	CARMUSTINE (addition of PSS) Inj 100 mg vial – 5% DV Dec-26 to 2028	710.00	1	BICNU
152	CARMUSTINE (delisting) Inj 100 mg vial.....	710.00	1	BiCNU S29 Novadoz
Note – BiCNU S29 and Novadoz inj 100 mg vial to be delisted from 1 December 2026.				
152	MELPHALAN (↓ price and addition of PSS) Inj 50 mg vial – 5% DV Dec-26 to 2029	46.80	1	Melpha
154	METHOTREXATE (new listing) Inj 7.5 mg prefilled syringe.....	29.17	1	Methotrexate Pharmascience
156	NIRAPARIB (delisting) → Cap 100 mg	8,929.84	56	Zejula
Note – Zejula cap 100mg to be delisted from 1 October 2026.				
159	TEMOZOLOMIDE (new listing) → Cap 5 mg	12.70	5	Temozolomide (Devatis)
159	TEMOZOLOMIDE (amended restriction criteria – affected criteria shown only) → Cap 5 mg	9.13	5	Temaccord Temozolomide Taro Temozolomide (Devatis)
		12.70	5	Temaccord
	→ Cap 20 mg	16.38	5	Temaccord
	→ Cap 100 mg	35.98	5	Temaccord
	→ Cap 140 mg	50.12	5	Temaccord
	→ Cap 250 mg	86.34	5	Temaccord

Restricted

Initiation - Neuroendocrine tumours

Re-assessment required after 9 months

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
- 4 Temozolomide to be discontinued at disease progression

Continuation - Neuroendocrine tumours

Re-assessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment

Note: Indication marked with a * is an unapproved indication. Temozolomide is not subsidised for the treatment of relapsed high grade glioma.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2026 (continued)

172	SUNITINIB (amended restriction criteria – affected criteria shown only)			
	→ Cap 12.5 mg – 5% DV Mar-26 to 2027	103.11	28	Sunitinib Rex
	→ Cap 25 mg – 5% DV Mar-26 to 2027	203.15	28	Sunitinib Rex
	→ Cap 50 mg – 5% DV May-26 to 2027	343.19	28	Sunitinib Rex
	Restricted			
	Continuation – GIST			
	<i>Re-assessment required after 6 months</i>			
	Both:			
	The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:			
	1– Any of the following:			
	1.1 The patient has had a complete response (disappearance of all lesions and no new lesions) or;			
	1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease) or;			
	1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression and;			
	2– The treatment remains appropriate and the patient is benefiting from treatment			
	Continuation – GIST pandemic circumstances			
	<i>Re-assessment required after 6 months</i>			
	Both All of the following:			
	1– The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and			
	2–1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and			
	3–2 Sunitinib is to be discontinued at disease progression; and			
	4– The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.			
	Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.			
177	TAMOXIFEN CITRATE (addition of PSS)			
	Tab 10 mg – 5% DV Dec-26 to 2029	15.00	60	Tamoxifen Sandoz
	Tab 20 mg – 5% DV Dec-26 to 2029	5.32	60	Tamoxifen Sandoz
179	ETANERCEPT (amended restriction criteria – new criteria shown only)			
	→ Inj 25 mg autoinjector	690.00	4	Enbrel
	→ Inj 25 mg vial	690.00	4	Enbrel
	→ Inj 50 mg autoinjector	1,050.00	4	Enbrel
	→ Inj 50 mg syringe	1,050.00	4	Enbrel
	Restricted			
	Initiation - Stevens-Johnson syndrome/toxic epidermal necrolysis			
	Patient has confirmed or suspected Stevens-Johnson syndrome or toxic epidermal necrolysis			
202	BENRALIZUMAB (new listing)			
	→ Inj 30 mg per ml, 1 ml prefilled pen	3,539.00	1	Fasenra
	Note – this is a new Pharmacode listing, 2731843.			
258	BACILLUS CALMETTE-GUERIN (BCG) († price)			
	→ Inj 2-8 × 10 ⁸ CFU vial	182.45	1	OncoTICE

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2026 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

265	PROMETHAZINE HYDROCHLORIDE Inj 25 mg per ml, 1 ml ampoule	52.73	25	XGen
267	BUDESONIDE WITH GLYCOPYRRONIUM AND EFORMOTEROL (new listing) → Aerosol inhaler budesonide 160 mcg with glycopyrronium 7.2 mcg and formoterol 5 mcg per dose.....	79.15	120 dose	Breztri Aerosphere
Note – This is a new Pharmacode listing, 2730936.				

SENSORY ORGANS

280	CYCLOPENTOLATE HYDROCHLORIDE (↑ price) Eye drops 1%	68.52	15 ml	Cyclogyl
280	TROPICAMIDE (↑ price) Eye drops 0.5%	33.89	15 ml	Mydriacyl
	Eye drops 1%	54.71	15 ml	Mydriacyl
281	PARAFFIN LIQUID WITH WOOL FAT (new listing) Eye oint 3% with wool fat 3%	3.63	3.5 g	Poly-Visc
Note – this is a new Pharmacode listing, 2718626.				

VARIOUS

285	IODIXANOL (↑ price) Inj 270 mg per ml (iodine equivalent), 50 ml bottle	305.00	10	Visipaque
	Inj 270 mg per ml (iodine equivalent), 100 ml bottle	560.00	10	Visipaque
	Inj 320 mg per ml (iodine equivalent), 50 ml bottle	310.00	10	Visipaque
	Inj 320 mg per ml (iodine equivalent), 100 ml bottle	565.00	10	Visipaque
	Inj 320 mg per ml (iodine equivalent), 200 ml bottle	1,130.00	10	Visipaque
285	IOHEXOL (↑ price) Inj 240 mg per ml (iodine equivalent), 50 ml bottle	140.00	10	Omnipaque
	Inj 300 mg per ml (iodine equivalent), 10 ml bottle	109.00	10	Omnipaque
	Inj 300 mg per ml (iodine equivalent), 50 ml bottle	145.00	10	Omnipaque
	Inj 300 mg per ml (iodine equivalent), 100 ml bottle	240.00	10	Omnipaque
	Inj 350 mg per ml (iodine equivalent), 50 ml bottle	150.00	10	Omnipaque
	Inj 350 mg per ml (iodine equivalent), 100 ml bottle	252.00	10	Omnipaque
	Inj 350 mg per ml (iodine equivalent), 200 ml bottle	522.00	10	Omnipaque
	Inj 350 mg per ml, 500 ml bottle	785.00	6	Omnipaque

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2026 (continued)

SPECIAL FOODS

307 PAEDIATRIC ORAL FEED 1 KCAL/ML (new listing)
 → Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml,
 200 ml bottle..... 1.33 1 Pediasure (chocolate)
 Note – This is a new Pharmacode listing, 2731592. Pharmacode 2705754 to be delisted from 1 August 2026.

Effective 1 June 2026

SPECIAL FOODS

303 AMINO ACID FORMULA (new listing)
 → Powder 13.5 g protein, 52 g carbohydrate and
 24.5 g fat per 100 g, can..... 55.61 400 g Neocate Gold (Unflavoured)
 Note – This is a new Pharmacode listing, 2732513.

Index

Pharmaceuticals and brands

A			
Advantan	9	IOHEXOL..... 14	
Alchemy Oxybutynin	9	Ipca-Ciprofloxacin	9
ALFENTANIL	11	K	
AMINO ACID FORMULA	15	Kenacort-A 10.....	9
APO-Ursodeoxycholic Acid.....	7	Kenacort-A 40.....	9
B		Kenalog in Orabase	7
BACILLUS CALMETTE-GUERIN (BCG).....	13	L	
BENRALIZUMAB	13	LANSOPRAZOLE.....	7
BiCNU.....	12	Lansoprazole (Viatris)	7
BiCNU S29.....	12	M	
Breztri Aerosphere.....	14	MACROGOL 3350 WITH POTASSIUM CHLORIDE AND	
BUDESONIDE WITH GLYCOPYRRONIUM AND		SODIUM CHLORIDE WITH/WITHOUT SODIUM	
EFOMOTEROL	14	SULFATE, SODIUM ASCORBATE, ASCORBIC ACID.....	7
C		MACROGOL 3350 WITH POTASSIUM CHLORIDE,	
CALCITONIN	9	SODIUM BICARBONATE AND SODIUM CHLORIDE.....	7
CARMUSTINE	12	MAGNESIUM SULPHATE.....	7
CEFALEXIN	9	MEBEVERINE HYDROCHLORIDE	7
Cefalexin Sandoz.....	9	Melpha	12
CHLORAMPHENICOL	10	MELPHALAN.....	12
CINCHOCAINE HYDROCHLORIDE WITH		MEROPENEM.....	9
HYDROCORTISONE.....	7	Meropenem-AFT	9
CIPROFLOXACIN	9	Metalyse	8
COLCHICINE	11	METARAMINOL.....	8
Colchicine Indoco	11	METHOTREXATE.....	12
Colofac	7	Methotrexate Pharmascience.....	12
Cyclogyl.....	14	METHYLPREDNISOLONE ACEPONATE	9
CYCLOPENTOLATE HYDROCHLORIDE	14	Miacalcic	9
D		Movicol	7
DARUNAVIR.....	10	MOXIFLOXACIN.....	10
Darunavir Viatris.....	10	Moxifloxacin Kabi.....	10
Diflucan	10	Moximed.....	10
E		MULTIVITAMINS	7
EFAVIRENZ WITH EMTRICITABINE AND		Mvite	7
TENOFOVIR DISOPROXIL	10	Mydriacyl.....	14
EMULSIFYING OINTMENT	9	N	
Enbrel	13	Neocate Gold (Unflavoured).....	15
EPHEDRINE	8	NIMODIPINE.....	8
Ephedrine Aguettant	8	Nimotop.....	8
Ephedrine Juno	8	NIRAPARIB	12
ETANERCEPT.....	13	Novadoz	12
Evara Emulsifying Ointment.....	9	O	
EZETIMIBE	8	Omnipaque	14
Ezetimibe Sandoz.....	8	OncoTICE.....	13
F		OXYBUTYNYN	9
Fasenra.....	13	P	
FEBUXOSTAT	11	Pacimol	11
Febuxostat (Teva)	11	PAEDIATRIC ORAL FEED 1 KCAL/ML	15
FLUCONAZOLE.....	10	PARACETAMOL	11
G		PARAFFIN LIQUID WITH WOOL FAT	14
Gonadron.....	9	Pediasure (chocolate)	15
I		Plenvu	7
IODIXANOL	14	Poly-Visc	14
		Proctosedyl.....	7

Index

Pharmaceuticals and brands

PROMETHAZINE HYDROCHLORIDE.....	14	Temozolomide (Devatis).....	12
Q		Temozolomide Taro	12
Quetapel	11	TENECTEPLASE	8
QUETIAPINE.....	11	Tenofovir Efavirenz Emtricitabine (Mylan)	10
R		TERIFLUNOMIDE.....	11
Rifadin	10	Teriflunomide Aurobindo	11
RIFAMPICIN	10	TESTOSTERONE UNDECANOATE	9
Rizamelt.....	11	THIAMINE HYDROCHLORIDE	7
RIZATRIPTAN.....	11	Thiamine-REX	7
Rizatriptan Rising	11	Torbay	8
Rizatriptan Viatris	11	TRIAMCINOLONE ACETONIDE.....	7, 9
ROSUVASTATIN.....	8	TROPICAMIDE	14
Rosuvastatin Mylan	8	U	
S		Ural.....	9
SIMVASTATIN	8	URSODEOXYCHOLIC ACID	7
Simvastatin Viatris.....	8	V	
SODIUM CITRO-TARTRATE.....	9	VALACICLOVIR	10
SUNITINIB	13	Valaciclovir Viatris	10
Sunitinib Rex.....	13	VANCOMYCIN	10
SUXAMETHONIUM CHLORIDE	11	Vancomycin Viatris	10
T		Visipaque.....	14
TAMOXIFEN CITRATE.....	13	X	
Tamoxifen Sandoz.....	13	XGen.....	14
Temaccord	12	Z	
TEMOZOLOMIDE.....	12	Zejula	12

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

